Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 17/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.57 |
| ▸ | PTGIR | P43119 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525785 | 0.91 | CHRM3 (0.67) | CHRM3CHRM2CHRM1PTGIR | |
| SCHEMBL6523641 | 0.89 | CHRM3 (0.58) | CHRM3CHRM2CHRM1PTGIR | |
| SCHEMBL16612446 | 0.87 | CHRM3 (0.67) | CHRM3CHRM2CHRM1PTGIR | |
| SCHEMBL6518937 | 0.87 | CHRM3 (0.67) | CHRM3CHRM2CHRM1PTGIR | |
| SCHEMBL6521801 | 0.87 | CHRM3 (0.67) | CHRM3CHRM2CHRM1PTGIR | |
| SCHEMBL6521781 | 0.87 | CHRM3 (0.68) | CHRM3CHRM2CHRM1PTGIR | |
| SCHEMBL6520642 | 0.86 | CHRM3 (0.65) | CHRM3CHRM2CHRM1PTGIR | |
| SCHEMBL29019382 | 0.85 | PTGIR (0.56) | CHRM3PTGIR | |
| SCHEMBL29019402 | 0.84 | PTGIR (0.64) | PTGIR | |
| SCHEMBL6517987 | 0.83 | CHRM3 (0.68) | CHRM3CHRM2CHRM1PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3884934-B1 | PHARMACEUTICAL COMPOSITION COMPRISING: 2-(((1R,4R)-4-(((4-CHLOROPHENYL)(PHENYL)CARBAMOYLOXY)METHYL)CYCLOHEXYL)METHOXY)ACETIC ACID | ARENA PHARM INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20200375930-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10668033-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20170360730-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-2280696-B9 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150126527-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| EP-2857015-A1 | Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8895776-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2280696-B1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | CHRM3 2820/4885CHRM2 1760/4885CHRM1 1763/4885 |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER2 | CHRM3 1275/4885CHRM2 615/4885CHRM1 1074/4885 |
| US-20170360730-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | CHRM3 2817/4885CHRM2 1755/4885CHRM1 1770/4885 |
| US-20200375930-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | CHRM3 2817/4885CHRM2 1755/4885CHRM1 1770/4885 |
| US-20150126527-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | CHRM3 2817/4885CHRM2 1755/4885CHRM1 1770/4885 |
| US-10668033-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | PTGIR, PTGIS, TBXA2R | CHRM3 2817/4885CHRM2 1755/4885CHRM1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.